An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Alpha Tau to Participate in November Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Alpha Tau Medical Ltd. announced that it will participate in several investor conferences in November 2023, including the Emerging Growth Conference, Jefferies London Healthcare Conference, and Piper Sandler 35th Annual Healthcare Conference.
Positive
None.
Negative
None.
JERUSALEM, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, today announced that management will participate in the following investor conferences in November 2023.
If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available on EmergingGrowth.com and on the Emerging Growth YouTube Channel, http://www.YouTube.com/EmergingGrowthConference.
About Alpha Tau Medical Ltd.
Founded in 2016, Alpha Tau is an Israeli medical device company that focuses on research, development, and potential commercialization of the Alpha DaRT for the treatment of solid tumors. The technology was initially developed by Prof. Itzhak Kelson and Prof. Yona Keisari from Tel Aviv University.
About Alpha DaRT™
Alpha DaRT (Diffusing Alpha-emitters Radiation Therapy) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays, its short-lived daughters are released from the sources and disperse while emitting high-energy alpha particles with the goal of destroying the tumor. Since the alpha-emitting atoms diffuse only a short distance, Alpha DaRT aims to mainly affect the tumor, and to spare the healthy tissue around it.
Alpha Tau Medical will participate in the Emerging Growth Conference, Jefferies London Healthcare Conference, and Piper Sandler 35th Annual Healthcare Conference.
The conferences will include company presentations, 1-on-1 meetings, fireside chats, and webcasts.
The Emerging Growth Conference will take place on Thursday, November 2nd, 2023, in a virtual format. The Jefferies London Healthcare Conference will be held on Wednesday, November 15th, 2023, in London. The Piper Sandler 35th Annual Healthcare Conference will take place on Tuesday, November 28th, 2023, in New York, NY.
Attendees can register for the conferences by reaching out to their Jefferies and Piper Sandler representatives. They can also register on the Emerging Growth website.
Yes, an archived webcast will be made available on EmergingGrowth.com and the Emerging Growth YouTube Channel.
alpha tau medical (http://www.alphataumedical.com/) focuses on research, development and commercialization of alpha dart (diffusing alpha-emitters radiation therapy) for the treatment of solid cancer tumors. alpha dart technology, initially developed at tel aviv university, was shown to be effective and safe for treating different types of cancer in multiple animal studies. the company is running its first clinical trial in several sites in the eu. breakthrough technology for cancer treatment the alpha dart breakthrough technology utilizes alpha radiation to treat cancer and enables highly potent and conformal radiotherapy. alpha dart treats solid tumors with interstitial radioactive seeds that continually release short-lived alpha emitting atoms into the tumor.
